LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Favipiravir-resistant influenza A virus shows potential for transmission.

    Daniel H Goldhill / Ada Yan / Rebecca Frise / Jie Zhou / Jennifer Shelley / Ana Gallego Cortés / Shahjahan Miah / Omolola Akinbami / Monica Galiano / Maria Zambon / Angie Lackenby / Wendy S Barclay

    PLoS Pathogens, Vol 17, Iss 6, p e

    2021  Volume 1008937

    Abstract: Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R ... ...

    Abstract Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical relevance of these mutations is unclear as the mutations have not been found in natural isolates and it is unknown whether viruses harbouring these mutations would replicate or transmit in vivo. Here, we infected ferrets with a mix of wild type p(H1N1) 2009 and corresponding favipiravir-resistant virus and tested for replication and transmission in the absence of drug. Favipiravir-resistant virus successfully infected ferrets and was transmitted by both contact transmission and respiratory droplet routes. However, sequencing revealed the mutation that conferred resistance, K229R, decreased in frequency over time within ferrets. Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R. We demonstrated that this fitness advantage of PA P653L in the background of our starting virus A/England/195/2009 was due to a maladapted PA in first wave isolates from the 2009 pandemic. We show there is no fitness advantage of P653L in more recent pH1N1 influenza A viruses. Therefore, whilst favipiravir-resistant virus can transmit in vivo, the likelihood that the resistance mutation is retained in the absence of drug pressure may vary depending on the genetic background of the starting viral strain.
    Keywords Immunologic diseases. Allergy ; RC581-607 ; Biology (General) ; QH301-705.5
    Subject code 616
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohortResearch in context

    Peter D. Kirwan / Victoria J. Hall / Sarah Foulkes / Ashley D. Otter / Katie Munro / Dominic Sparkes / Anna Howells / Naomi Platt / Jonathan Broad / David Crossman / Chris Norman / Diane Corrigan / Christopher H. Jackson / Michelle Cole / Colin S. Brown / Ana Atti / Jasmin Islam / Anne M. Presanis / Andre Charlett /
    Daniela De Angelis / Susan Hopkins / Tracy Lewis / Steve Bain / Rebeccah Thomas / John Geen / Carla Pothecary / Sean Cutler / John Northfield / Cathy Price / Johanne Tomlinson / Sarah Knight / Emily Macnaughton / Ekaterina Watson / Rajeka Lazarus / Aaran Sinclair / Joanne Galliford / Bridgett Masunda / Tabitha Mahungu / Alison Rodger / Esther Hanison / Simon Warren / Swati Jain / Mariyam Mirfenderesky / Natasha Mahabir / Rowan Pritchard-Jones / Diane Wycherley / Claire Gabriel / Elijah Matovu / Philippa Bakker / Simantee Guha / S. Gormley / James Pethick / Georgina Butt / Stacey Pepper / Luke Bedford / Paul Ridley / Jane Democratis / Manjula Meda / Anu Chawla / Fran Westwell / Nagesh Kalakonda / Sheena Khanduri / Allison Doel / Sumita Pai / Christian Hacon / Davis Nwaka / Veronica Mendez Moro / A. Moody / Cressida Auckland / Stephanie Prince / Thushan de Silva / Helen Shulver / A. Shah / C. Jones / Banerjee Subhro-Osuji / Angela Houston / Tim Planche / Martin Booth / Christopher Duff / Jonnie Aeron-Thomas / Ray Chaudhuri / David Hilton / Hannah Jory / Zehra'a Al-Khafaji / Philippa Kemsley / Ruth Longfellow / David Boss / Simon Brake / Louise Coke / Ngozi Elumogo / Scott Latham / Chinari Subudhi / Ina Hoad / Claire Thomas / Nihil Chitalia / Tracy Edmunds / Helen Ashby / John Elliott / Beverley Wilkinson / Abby Rand / Catherine Thompson / K. Agwuh / Anna Grice / Kelly Moran / Vijayendra Waykar / Yvonne Lester / Lauren Sach / Kathryn Court / Nikki White / Clair Favager / Kyra Holliday / Jayne Harwood / Brendan Payne / Karen Burns / Lynda Fothergill / Alejandro Arenas-Pinto / Abigail Severn / Kerryanne Brown / Katherine Gray / Jane Dare / Qi Zheng / Kathryn Hollinshead / Robert Shorten / Alun Roebuck / Christopher Holmes / Martin Wiselka / Barzo Faris / Liane Marsh / Clare McAdam / Lisa Ditchfield / Zaman Qazzafi / G. Boyd / N. Wong / Sarah Brand / Jack Squires / John Ashcroft / Ismaelette Del Rosario / Joanne Howard / Emma Ward / Gemma Harrison / Joely Morgan / Claire Corless / Ruth Penn / Nick Wong / Manny Bagary / Nadezda Starkova / Mandy Beekes / Mandy Carnahan / Shivani Khan / Shekoo Mackay / Keneisha Lewis / Graham Pickard / Joy Dawson / Lauren Finlayson / Euan Cameron / Anne Todd / Sebastien Fagegaltier / Sally Mavin / Alexandra Cochrane / Andrew Gibson / Sam Donaldson / Kate Templeton / Martin Malcolm / Beth Smith / Devesh Dhasmana / Susan Fowler / Antonia Ho / Michael Murphy / Claire Beith / Manish Patel / Elizabeth Boyd / Val Irvine / Alison Grant / Rebecca Temple-Purcell / Clodagh Loughrey / Elinor Hanna / Frances Johnston / Angel Boulos / Fiona Thompson / Yuri Protaschik / Susan Regan / Tracy Donaghy / Maurice O'Kane / Omolola Akinbami / Paola Barbero / Tim Brooks / Meera Chand / Ferdinando Insalata / Palak Joshi / Anne-Marie O'Connell / Mary Ramsay / Ayoub Saei / Maria Zambon / Ezra Linley / Simon Tonge / Enemona Adaji / Omoyeni Adebiyi / Nick Andrews / Joanna Conneely / Paul Conneely / Angela Dunne / Simone Dyer / Hannah Emmett / Nipunadi Hettiarachchi / Nishanthan Kapirial / Jameel Khawam / Edward Monk / Sophie Russell / Andrew Taylor-Kerr / Jean Timeyin / Silvia D'Arcangelo / Cathy Rowe / Amanda Semper / Eileen Gallagher / Robert Kyffin / Lisa Cromey / Desmond Areghan / Jennifer Bishop / Melanie Dembinsky / Laura Dobbie / Josie Evans / David Goldberg / Lynne Haahr / Annelysse Jorgenson / Ayodeji Matuluko / Laura Naismith / Desy Nuryunarsih / Alexander Olaoye / Caitlin Plank / Lesley Price / Nicole Sergenson / Sally Stewart / Andrew Telfer / Jennifer Weir / Ellen De Lacy / Yvette Ellis / Susannah Froude / Guy Stevens / Linda Tyson / Susanna Dunachie / Paul Klenerman / Chris Duncan / Rebecca Payne / Lance Turtle / Alex Richter / Thushan De Silva / Eleanor Barnes / Daniel Wootton / Oliver Galgut / Jonathan Heeney / Helen Baxendale / Javier Castillo-Olivares / Rupert Beale / Edward Carr / Wendy Barclay / Maya Moshe / Massimo Palmarini / Brian Willett / John Kenneth Baillie / Jennie Evans / Erika Aquino

    The Lancet Regional Health. Europe, Vol 36, Iss , Pp 100809- (2024)

    1481  

    Abstract: Summary: Background: The protection of fourth dose mRNA vaccination against SARS-CoV-2 is relevant to current global policy decisions regarding ongoing booster roll-out. We aimed to estimate the effect of fourth dose vaccination, prior infection, and ... ...

    Abstract Summary: Background: The protection of fourth dose mRNA vaccination against SARS-CoV-2 is relevant to current global policy decisions regarding ongoing booster roll-out. We aimed to estimate the effect of fourth dose vaccination, prior infection, and duration of PCR positivity in a highly-vaccinated and largely prior-COVID-19 infected cohort of UK healthcare workers. Methods: Participants underwent fortnightly PCR and regular antibody testing for SARS-CoV-2 and completed symptoms questionnaires. A multi-state model was used to estimate vaccine effectiveness (VE) against infection from a fourth dose compared to a waned third dose, with protection from prior infection and duration of PCR positivity jointly estimated. Findings: 1298 infections were detected among 9560 individuals under active follow-up between September 2022 and March 2023. Compared to a waned third dose, fourth dose VE was 13.1% (95% CI 0.9 to 23.8) overall; 24.0% (95% CI 8.5 to 36.8) in the first 2 months post-vaccination, reducing to 10.3% (95% CI −11.4 to 27.8) and 1.7% (95% CI −17.0 to 17.4) at 2–4 and 4–6 months, respectively. Relative to an infection >2 years ago and controlling for vaccination, 63.6% (95% CI 46.9 to 75.0) and 29.1% (95% CI 3.8 to 43.1) greater protection against infection was estimated for an infection within the past 0–6, and 6–12 months, respectively. A fourth dose was associated with greater protection against asymptomatic infection than symptomatic infection, whilst prior infection independently provided more protection against symptomatic infection, particularly if the infection had occurred within the previous 6 months. Duration of PCR positivity was significantly lower for asymptomatic compared to symptomatic infection. Interpretation: Despite rapid waning of protection, vaccine boosters remain an important tool in responding to the dynamic COVID-19 landscape; boosting population immunity in advance of periods of anticipated pressure, such as surging infection rates or emerging variants of concern. Funding: UK ...
    Keywords SARS-CoV-2 ; Vaccine effectiveness ; Asymptomatic ; Symptomatic ; Healthcare worker ; Cohort study ; Public aspects of medicine ; RA1-1270
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top